Small molecule inhibitors of oncogenic miR-21

致癌 miR-21 的小分子抑制剂

基本信息

  • 批准号:
    10081975
  • 负责人:
  • 金额:
    $ 24.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-14 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary: Company development - Ithax Pharmaceuticals is a new spin-off biotechnology company located in Seattle and focused on developing small drug-like molecules that target non-coding RNAs in cancer and other chronic diseases. The experience of its founders’ spans drug design, RNA structure, cancer biology and biotech management, and includes the successful spin offs of several biotech companies. It gives the company an unmatched experience in the technological and commercial development of new companies in the RNA- oncology space. This Phase I STTR proposal lays out a series of experiments, beyond the scope of academic discovery, critical to advance and de-risk the commercialization plans of Ithax in the eyes of investors and pharmaceutical partners. Completion of this project will help the company fill gaps left in the academic discoveries of the founders by providing the data required to initiate medicinal chemistry optimization under a subsequent already planned phase II SBIR, and to successfully raise private capital needed for pre-clinical and clinical development. Technology - The proto-oncogenic non-coding RNA miR-21 is over-expressed in nearly every human tumor. Its over-expression is linked to unfavorable patient prognosis in multiple cancers and resistance to chemotherapeutic and immunotherapeutic treatment. Accumulating evidence in many cellular and multiple small animal models of cancers demonstrates that pharmacological inhibition of miR-21 would stop the progression of even late stage cancers, which are ‘addicted’ to this oncomiR, reduce chemo-resistance and potentiate checkpoint immunotherapy. Ithax’s first lead small molecule emerges from a collaboration between the University of Washington and the MD Anderson Cancer Center to identify new inhibitors of miRNA biogenesis. Preliminary data demonstrate that ITX-0052, a ‘Lipinski’ drug-like molecule with very safe in vitro pharmacological profile, inhibits miR-21 accumulation and reduces proliferation of gastric and pancreatic cancer cells with low M IC50 by binding directly to pre-miR-21. This project will establish the structural, biochemical and cellular mechanism of inhibition; and evaluate safety of administration, pharmacokinetics, pharmacodynamics and efficacy in murine models of gastric cancer.
项目总结:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

George A Calin其他文献

George A Calin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('George A Calin', 18)}}的其他基金

miR-155 targeted therapeutics for precision medicine in lung cancer
miR-155靶向治疗用于肺癌精准医疗
  • 批准号:
    10225382
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
miR-155 targeted therapeutics for precision medicine in lung cancer
miR-155靶向治疗用于肺癌精准医疗
  • 批准号:
    10460112
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
miR-155 targeted therapeutics for precision medicine in lung cancer
miR-155靶向治疗用于肺癌精准医疗
  • 批准号:
    9755389
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
miR-155 targeted therapeutics for precision medicine in lung cancer
miR-155靶向治疗用于肺癌精准医疗
  • 批准号:
    9976985
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
HPV Communication to Microenvironment via Exosomes
HPV 通过外泌体与微环境通讯
  • 批准号:
    8843659
  • 财政年份:
    2013
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel extra cellular RNA-based combinatorial RNA inhibition therapy
基于细胞外RNA的新型组合RNA抑制疗法
  • 批准号:
    8711594
  • 财政年份:
    2013
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel extra cellular RNA-based combinatorial RNA inhibition therapy
基于细胞外RNA的新型组合RNA抑制疗法
  • 批准号:
    8962199
  • 财政年份:
    2013
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel extra cellular RNA-based combinatorial RNA inhibition therapy
基于细胞外RNA的新型组合RNA抑制疗法
  • 批准号:
    9128780
  • 财政年份:
    2013
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel extra cellular RNA-based combinatorial RNA inhibition therapy
基于细胞外RNA的新型组合RNA抑制疗法
  • 批准号:
    8582255
  • 财政年份:
    2013
  • 资助金额:
    $ 24.91万
  • 项目类别:
MicroRNAs and other non-coding RNAs in Colorectal Metastasis
结直肠转移中的 MicroRNA 和其他非编码 RNA
  • 批准号:
    7653452
  • 财政年份:
    2009
  • 资助金额:
    $ 24.91万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 24.91万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 24.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了